牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc. has updated its prospectus supplement on July 22, 2024, to reflect an increase in the maximum aggregate gross sales price of its common stock offered through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. The increase adjusts the sales cap from the previously registered $1,253,603 to $1,774,640. As of the filing date, 3,969,076 shares have been sold under the agreement, amounting to an aggregate gross sales price of $1,197,073.32. The company's common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP', with a closing sale price of $0.271 per share on July 19, 2024. The ATM Offering terms remain unchanged, and the Sales Agreement is still in effect. The company's market value of outstanding common stock held by non-affiliates is approximately $5,154,331, based on a share price of $0.351 as of June 7, 2024. The company has emphasized the significant risks associated with investing in its common stock, as detailed in the 'Risk Factors' section of the Prospectus Supplement and Base Prospectus, and other SEC filings.
60 Degrees Pharmaceuticals, Inc. has updated its prospectus supplement on July 22, 2024, to reflect an increase in the maximum aggregate gross sales price of its common stock offered through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. The increase adjusts the sales cap from the previously registered $1,253,603 to $1,774,640. As of the filing date, 3,969,076 shares have been sold under the agreement, amounting to an aggregate gross sales price of $1,197,073.32. The company's common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP', with a closing sale price of $0.271 per share on July 19, 2024. The ATM Offering terms remain unchanged, and the Sales Agreement is still in effect. The company's market value of outstanding common stock held by non-affiliates is approximately $5,154,331, based on a share price of $0.351 as of June 7, 2024. The company has emphasized the significant risks associated with investing in its common stock, as detailed in the 'Risk Factors' section of the Prospectus Supplement and Base Prospectus, and other SEC filings.
60度藥品公司已於2024年7月22日更新其招股說明書補充，以反映其與WallachBeth Capital LLC簽訂的上市銷售協議通過掛牌發行的最大總銷售價格的增加。 該增加將銷售上限由先前註冊的125萬3603美元調整爲177萬4640美元。 截至申報日，已售出3969076股，總銷售價格爲1197073.32美元。該公司的普通股在納斯達克股票市場上交易，股票代碼爲'SXTP'，截至2024年7月19日的收盤價爲每股0.271美元。 ATm發行條款保持不變，銷售協議仍然有效。 截至2024年6月7日，被非關聯方持有的總普通股市值約爲515萬4331美元，以每股0.351美元的股價計算。公司強調投資其普通股涉及的重大風險，詳見招股說明書補充和基礎招股說明書中的'風險因素'部分以及其他SEC文件。
60度藥品公司已於2024年7月22日更新其招股說明書補充，以反映其與WallachBeth Capital LLC簽訂的上市銷售協議通過掛牌發行的最大總銷售價格的增加。 該增加將銷售上限由先前註冊的125萬3603美元調整爲177萬4640美元。 截至申報日，已售出3969076股，總銷售價格爲1197073.32美元。該公司的普通股在納斯達克股票市場上交易，股票代碼爲'SXTP'，截至2024年7月19日的收盤價爲每股0.271美元。 ATm發行條款保持不變，銷售協議仍然有效。 截至2024年6月7日，被非關聯方持有的總普通股市值約爲515萬4331美元，以每股0.351美元的股價計算。公司強調投資其普通股涉及的重大風險，詳見招股說明書補充和基礎招股說明書中的'風險因素'部分以及其他SEC文件。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了